VBL Therapeutics to Host Virtual R&D Day on April 6
March 30 2021 - 6:00AM
VBL Therapeutics (Nasdaq: VBLT) today announced that it will host a
virtual R&D Day for analysts and investors beginning at 10:00am
ET on Tuesday, April 6, 2021. The event will include presentations
from Professor Dror Harats, M.D, Chief Executive Officer, Dr.
Bradley Monk, M.D., FACS, FACOG, Chair of the OVAL Study Steering
Committee, and Dr. Tami Rachmilewitz, M.D, Vice President of
Clinical Development, and will focus on the Company’s
clinical-stage pipeline including lead program, VB-111. The live
event can be accessed at https://wsw.com/webcast/cc/vbl/1261656
Following the event, an archive will be available via the
“Events and Presentations” section of the VBL investor relations
website at
http://ir.vblrx.com/events-and-presentations/archived-events
For more information, please contact VBLRX@Burnsmc.com
About VBLVascular Biogenics Ltd., operating
as VBL Therapeutics, is a clinical stage biopharmaceutical
company focused on the discovery, development and commercialization
of first-in-class treatments for areas of unmet need in cancer and
immune/inflammatory indications. VBL has developed three platform
technologies: a gene-therapy based technology for targeting newly
formed blood vessels with focus on cancer, an antibody-based
technology targeting MOSPD2 for anti-inflammatory and
immuno-oncology applications, and the Lecinoxoids, a family of
small-molecules for immune-related indications. VBL’s lead oncology
product candidate, ofranergene obadenovec (VB-111), is an
investigational, first-in-class, targeted anti-cancer gene-therapy
agent that is being developed to treat a wide range of solid
tumors. VB-111 is currently being studied in a VBL-sponsored Phase
3 registration enabling trial for platinum-resistant ovarian
cancer.
CONTACT:Burns McClellan for VBL
TherapeuticsLee Roth (investors) / Ryo Imai
(media)lroth@burnsmc.com / rimai@burnsmc.com+1-212-213-0006
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From Apr 2024 to May 2024
Vascular Biogenics (NASDAQ:VBLT)
Historical Stock Chart
From May 2023 to May 2024